

Itziar Astigarraga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4795025/publications.pdf>

Version: 2024-02-01

78
papers

2,907
citations

257450

24
h-index

182427

51
g-index

91
all docs

91
docs citations

91
times ranked

4087
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical spectrum of COVID-19 and risk factors associated with severity in Spanish children. <i>European Journal of Pediatrics</i> , 2022, 181, 1105-1115.	2.7	19
2	Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma. <i>Cancers</i> , 2022, 14, 421.	3.7	0
3	Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP). <i>Clinical and Translational Oncology</i> , 2022, , 1.	2.4	1
4	A Three-Protein Panel to Support the Diagnosis of Sepsis in Children. <i>Journal of Clinical Medicine</i> , 2022, 11, 1563.	2.4	5
5	Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	1
6	Etoposide for Cytokine Storm Because of Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1678-1679.	0.8	2
7	Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e265.	4.0	23
8	Use of Antiangiogenic Therapies in Pediatric Solid Tumors. <i>Cancers</i> , 2021, 13, 253.	3.7	9
9	Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population. <i>Journal of Pediatrics</i> , 2021, 232, 287-289.e4.	1.8	56
10	EPCT-04. RESULTS OF A PHASE 1 STUDY OF THE ONCOLYTIC ADENOVIRUS DNX-2401 WITH RADIOTHERAPY FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2021, 23, i47-i47.	1.2	1
11	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. <i>Journal of Pediatrics</i> , 2021, 237, 65-70.e3.	1.8	8
12	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	10.7	93
13	Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas. <i>Cancers</i> , 2021, 13, 5436.	3.7	4
14	Importance of Timely Treatment Initiation in Infantile-Onset Pompe Disease, a Single-Centre Experience. <i>Children</i> , 2021, 8, 1026.	1.5	3
15	miRNA deregulation in childhood acute lymphoblastic leukemia: a systematic review. <i>Epigenomics</i> , 2020, 12, 69-80.	2.1	9
16	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28557.	1.5	31
17	Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia. <i>Epigenomics</i> , 2020, 12, 1949-1955.	2.1	2
18	Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. <i>Blood Advances</i> , 2020, 4, 3754-3766.	5.2	34

#	ARTICLE	IF	CITATIONS
19	Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2020, 40, 901-916.	3.8	33
20	Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia. <i>BMJ Open</i> , 2020, 10, e029642.	1.9	10
21	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. <i>Blood</i> , 2020, 135, 274-286.	1.4	81
22	CD300c costimulates IgE-mediated basophil activation, and its expression is increased in patients with cow's milk allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 700-711.e5.	2.9	15
23	Protocol for the study and treatment of primary immune thrombocytopenia: ITP-2018. <i>Anales De Pediatr�a (English Edition)</i> , 2019, 91, 127.e1-127.e10.	0.2	2
24	ECLIM-SEHOP, a new platform to set up and develop international academic clinical trials for childhood cancer and blood disorders in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1763-1770.	2.4	2
25	NMR-based newborn urine screening for optimized detection of inherited errors of metabolism. <i>Scientific Reports</i> , 2019, 9, 13067.	3.3	28
26	Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2019, 19, 564-569.	2.0	12
27	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. <i>Haematologica</i> , 2019, 104, 1822-1829.	3.5	71
28	A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis. <i>Cancer</i> , 2019, 125, 963-971.	4.1	26
29	Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2018, 19, 361-373.	1.3	16
30	Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2018, 18, 704-712.	2.0	24
31	Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity. <i>Epigenomics</i> , 2018, 10, 409-417.	2.1	8
32	Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 465-472.	3.1	36
33	Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment. <i>Pharmacogenomics</i> , 2018, 19, 1403-1412.	1.3	6
34	Involvement of SNPs in miR-3117 and miR-3689d2 in childhood acute lymphoblastic leukemia risk. <i>Oncotarget</i> , 2018, 9, 22907-22914.	1.8	18
35	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1508-1517.	3.8	112
36	Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2018, 132, 2088-2096.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Haemophagocytic syndromes: the importance of early diagnosis and treatment. <i>Anales De Pediatr�a (English Edition)</i> , 2018, 89, 124.e1-124.e8.	0.2	5
38	Infantile Pulmonary Teratoid Tumor. <i>New England Journal of Medicine</i> , 2018, 378, 2238-2240.	27.0	16
39	Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts. <i>Blood</i> , 2018, 132, 1567-1567.	1.4	0
40	SNPS in microRNAs associated with methotrexate plasma levels in Spanish children with acute lymphoblastic leukemia. <i>European Journal of Cancer</i> , 2017, 72, S143.	2.8	0
41	Management and early complications of totally implantable venous access port systems in 81 children diagnosed with cancer. <i>European Journal of Cancer</i> , 2017, 72, S146.	2.8	0
42	Involvement of SNPS in CDKN2A/B locus in childhood acute lymphoblastic leukemia susceptibility in the Spanish population. <i>European Journal of Cancer</i> , 2017, 72, S144.	2.8	0
43	Involvement of SNPS in mir3117 and mir3689 in pediatric acute lymphoblastic leukemia susceptibility. <i>European Journal of Cancer</i> , 2017, 72, S144.	2.8	0
44	Prophylaxis and therapy of tumor lysis syndrome in 115 pediatric patients diagnosed with hematological neoplasms. <i>European Journal of Cancer</i> , 2017, 72, S147.	2.8	0
45	Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. <i>Blood</i> , 2017, 130, 2728-2738.	1.4	418
46	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	1.8	50
47	Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 615-617.	7.0	12
48	Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population. <i>PLoS ONE</i> , 2017, 12, e0177421.	2.5	18
49	The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults. <i>Scientific Reports</i> , 2016, 6, 32693.	3.3	29
50	Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia. <i>Pharmacogenomics</i> , 2016, 17, 731-741.	1.3	61
51	Social/economic costs and health-related quality of life in patients with histiocytosis in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 67-78.	2.8	16
52	Somatic <i>DICER1</i> mutations in adult-onset pulmonary blastoma. <i>European Respiratory Journal</i> , 2016, 47, 1879-1882.	6.7	22
53	Involvement of miR-3117 in pediatric acute lymphoblastic leukemia susceptibility. <i>European Journal of Cancer</i> , 2016, 61, S29.	2.8	1
54	MicroRNA SNPs as novel markers of methotrexate toxicity in pediatric acute lymphoblastic leukemia. <i>European Journal of Cancer</i> , 2016, 61, S141-S142.	2.8	0

#	ARTICLE	IF	CITATIONS
55	MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 517-525.	1.5	30
56	Landscape of early clinical trials for childhood and adolescence cancer in Spain. <i>Clinical and Translational Oncology</i> , 2016, 18, 708-713.	2.4	4
57	Hemophagocytic Lymphohistiocytosis (HLH) in Langerhans Cell Histiocytosis (LCH): A Multicenter Retrospective Descriptive Study. <i>Blood</i> , 2016, 128, 707-707.	1.4	2
58	Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. <i>British Journal of Haematology</i> , 2015, 169, 241-248.	2.5	25
59	Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2162-2166.	1.5	20
60	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101
61	Predictive factors of severe multilobar pneumonia and shock in patients with influenza. <i>Emergency Medicine Journal</i> , 2014, 31, 301-307.	1.0	3
62	Social factors related to the clinical severity of influenza cases in Spain during the A (H1N1) 2009 virus pandemic. <i>BMC Public Health</i> , 2013, 13, 118.	2.9	20
63	Clinical features of influenza disease in admitted children during the first postpandemic season and risk factors for hospitalization: a multicentre Spanish experience. <i>Clinical Microbiology and Infection</i> , 2013, 19, E157-E162.	6.0	12
64	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workup, and treatment for patients till the age of 18 years. <i>Pediatric Blood and Cancer</i> , 2013, 60, 175-184.	1.5	496
65	Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza. <i>Clinical Infectious Diseases</i> , 2013, 57, 167-175.	5.8	112
66	Different prognosis in hospitalized patients with influenza one season after the pandemic 2009 A/H1N1 influenza of 2009-2010 in Spain. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 1336-1342.	3.4	6
67	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. <i>Blood</i> , 2013, 121, 5006-5014.	1.4	343
68	Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. <i>Health Policy</i> , 2012, 108, 19-26.	3.0	38
69	2009 H1N1: risk factors for hospitalization in a matched case-control study. <i>European Journal of Pediatrics</i> , 2012, 171, 1127-1131.	2.7	13
70	Hemophagocytic lymphohistiocytosis in a pancreas-kidney transplant recipient: response to dexamethasone and cyclosporine. <i>Clinical Nephrology</i> , 2008, 70, 82-86.	0.7	8
71	Simultaneous manifestation of fulminant infectious mononucleosis with haemophagocytic syndrome and B-cell lymphoma in X-linked lymphoproliferative disease. <i>European Journal of Pediatrics</i> , 2007, 166, 589-593.	2.7	11
72	Near fatal cerebellar swelling in familial hemophagocytic lymphohistiocytosis. <i>Pediatric Neurology</i> , 2004, 30, 361-364.	2.1	17

#	ARTICLE	IF	CITATIONS
73	Reversible Cardiomyopathy Secondary to $\hat{\pm}$ -Interferon in an Infant. <i>Pediatric Cardiology</i> , 1999, 20, 293-294.	1.3	19
74	Hypereosinophilia due to Myiasis. <i>Acta Haematologica</i> , 1998, 99, 27-30.	1.4	25
75	Hydrops fetalis and fibrosarcoma: case report of an uncommon association. <i>European Journal of Pediatrics</i> , 1996, 156, 62-64.	2.7	10
76	Secondary central nervous system metastases in children with neuroblastoma. , 1996, 27, 529-533.		22
77	Use of Serological Markers as a Screening Test in Family Members of Patients with Celiac Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1994, 19, 304-309.	1.8	47
78	The novel p.Gly306Asp perforin mutation causes Familial Hemophagocytic Lymphohistiocytosis type 2 (FHL-2) probably due to a critical role of Gly306 in the pore-forming perforin domain.. <i>LymphoSign Journal</i> , 0, , .	0.2	0